Clinical trial
A Study of Treatment Success in Changing From Olanzapine to Long-acting…
NCT00216632 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00216632 |
|---|---|
| Title | A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™) |
| Official title | Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR) |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Psychotic Disorders |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 99 |
| Start date | Mar 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 7, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: